# Pacira Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pacira-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.pacira.com
- Total disclosed funding: $55M
- Latest round: Series A (Nov 15, 2008)
- Investors on record: 4

## About

Pacira Pharmaceuticals is a biotechnology company focused on developing innovative non-opioid therapies for effective pain management, primarily targeting surgical and musculoskeletal needs.Pacira Pharmaceuticals specializes in the development of non-opioid pain management therapies. Founded in the US, the company has evolved its business strategy through innovative product development. The company went public in February 2011, raising USD 42 mn with a pricing of 6 million shares at USD 7 per share. Pacira was established by a group of industry experts aiming to address the gap in safer pain management options.Pacira BioSciences specializes in innovative non-opioid therapies for pain management, including EXPAREL® (bupivacaine liposome injectable suspension), iovera°, and ZILRETTA® (triamcinolone acetonide extended-release injectable suspension). EXPAREL® is designed for postsurgical pain management, ensuring prolonged analgesia without opioid risks. ZILRETTA® is a long-acting corticosteroid injection targeting osteoarthritis-related knee pain, marketed primarily to healthcare providers across the United States, with goals of expanding availability to additional regions to offer safer pain management alternatives.In the most recent fiscal year 2024, Pacira Pharmaceuticals reported a revenue of USD 697.19 mn and an EBITDA of USD 5.41 mn. The company generates its revenue through direct sales of its trademarked products to healthcare providers, including hospitals and outpatient surgical centers, focusing on the adoption of its non-opioid pain management solutions.Going forward, Pacira Pharmaceuticals plans to expand its product line with new therapies aimed at pain management, although specific details on upcoming product launches have not been disclosed. The company is also targeting international markets for growth, with aspirations for broader availability of its products. The funding raised in the February 2011 IPO will support these initiatives, allowing the company to fuel research and development efforts while enhancing its market presence.

## Funding rounds

- Series A, Nov 15, 2008, $55M — OrbiMed Advisors, Sanderling Ventures, HBM Partners, MPM BioImpact

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A